After CEO Maselli's ascent, Catalent shakes up operations, taps new execs

A new age is dawning at Catalent after the manufacturing juggernaut Tuesday unveiled a new operating structure to home in on its biologics business plus its pharmaceuticals and consumer health arm.

The shift comes just days after the company’s new chief executive Alessandro Maselli took the reins from longtime CEO John Chiminski, who’s pivoted to executive chair of the manufacturer’s board of directors.

Now, rather than reporting on the performance of four different business segments, the new Maselli-led Catalent will focus on the two areas above—biologics, plus pharmaceuticals and consumer health—which each represent roughly half of the company’s total revenue.

Aside from the financial reporting shift, Catalent has also named Aris Gennadios, Ph.D., group president of the company’s new pharma and consumer health unit. The new unit fuses Catalent’s former softgel and oral technologies arm with the company’s oral and specialty delivery and clinic supply service segments. Gennadios previously led the softgel and oral technologies unit starting in 2013, Catalent added.

Further, Catalent said it aims to upgrade its customer offerings and potentially gin up growth for the new unit by putting dedicated teams on its pharmaceutical, consumer health and clinical development and supply solutions businesses.

Maselli, Chiminski and Gennadios aren’t the only Catalent execs playing C-suite musical chairs. In tandem with the restructuring, Catalent has named Jonathan Arnold, president of oral and specialty delivery since 2017, as Catalent’s new chief commercial officer and head of transformation.

Meanwhile, Steven Fasman is set to assume the newly minted role of chief administrative officer, Catalent added. Fasman had previously served as general council since 2014. In his new position, Fasman will spearhead certain administrative functions, including legal and compliance issues, information technology, engineering, procurement, government affairs and “various ESG-related departments.”

Finally, Karen Flynn, currently Catalent’s senior vice president and chief commercial officer, has announced her plan to retire, the company said.

“I am immensely grateful for [Flynn’s] leadership, innovative thinking, and steadfast commitment to the company,” Maselli said in a statement.

Catalent’s fortunes have risen sharply over the past two years, propelled by the company’s various COVID-19 production partnerships, which include deals with Moderna on its mRNA-based shot as well as pacts with Johnson & Johnson and AstraZeneca on their more traditional vaccines. The company is also chipping in on several investigational vaccine candidates in addition to an experimental antiviral and a monoclonal antibody drug prospect.